Project Grant R41CA250616

This federal Project Grant award of $269,280.00 was provided by the National Cancer Institute (NCI), which administers the Cancer Treatment Research program (CFDA 93.395), to Cold Spring Harbor Laboratory (CSHL) on February 3, 2025. The award supports a research project titled "Proximity-Triggered, Mutant-Specific Modification of K-RAS(G12C) with Local Polypharmaceutical Release". The project aims to develop a novel targeted approach for cancers driven by the K-RAS(G12C) mutation,...

This $1,398,552 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Avantgen Inc., a San Diego-based biotechnology company, in conducting preliminary IND-enabling studies for a novel antibody therapy targeting the Jagged-1 pathway in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The key products and services to be delivered under this grant include cell line development, early chemistry and manufacturing controls (CMC)...

This Project Grant award, with ID R01CA292596, was provided by the National Cancer Institute (NCI) under the federal Cancer Treatment Research program (CFDA 93.395). The award totals $738,698.00 and runs from March 7, 2025 to February 28, 2030. The primary objective is to evaluate the combination of anti-CD38 targeted alpha therapy (TAT) and total marrow irradiation (TMLI) conditioning regimens for the treatment of relapsed/refractory acute myelogenous leukemia (AML) in patients over 60 years...

This $800,000 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to develop a longer-acting version of the novel mammalian enzyme drug L-asparaginase (EBD-300) to improve its feasibility for pan-cancer therapy. The key products and services to be delivered under this 2-year award include: Engineering and testing next-generation EBD-300 variants with extended in vivo half-life to address the need for a longer-acting asparaginase that can be used as...

This Cooperative Agreement award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $4,653,104 in funding to the Massachusetts Institute of Technology (MIT) to discover and develop small molecule agents that can modulate the function of the PAX3-FOXO1 fusion oncoprotein, which drives the progression of fusion-positive alveolar rhabdomyosarcoma (FP-RMS), a highly fatal childhood cancer. The project involves a collaborative team of chemical biologists,...

This Project Grant award of $356,850 from the National Cancer Institute's Cancer Treatment Research Program (CFDA 93.395) supports a research project at the Medical College of Wisconsin to investigate the use of EGFR inhibitors in colorectal cancer patients with mutant RAS genes. The key objectives are to: 1) Conduct functional mechanistic studies to test RAS mutants and their ability to bind the NF1 tumor suppressor for EGFR inhibitor sensitivity; 2) Pharmacologically target wild-type RAS in...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $399,970 to Duo Oncology Inc. to develop DUO-207, an ultrasmall nanoparticle formulation designed to improve the delivery and efficacy of combination chemotherapy for advanced pancreatic cancer. The key product being developed under this award is DUO-207, which combines a polymer-conjugated gemcitabine and paclitaxel in a single 14nm nanoparticle. This novel formulation...

This $503,194 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Seattle Children's Hospital aimed at developing an innovative multispecific T cell engager (MTE) therapy to treat neuroblastoma and other pediatric solid tumors. The key products and services being delivered under this 2-year award include: 1) Determining the efficacy of the R2P3 MTE, which binds to the ROR1 and PD-L1 tumor targets as well as CD3 on T cells,...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $215,311 to the University of Texas Health Science Center at Houston to conduct preclinical research on antibody-drug conjugates (ADCs) targeting the GPR56 receptor for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) develop and evaluate GPR56-targeting ADCs for potent and selective killing of TNBC cells, 2) assess the safety and efficacy of lead GPR56...

The National Cancer Institute (NCI), through its Cancer Treatment Research program (CFDA 93.395), has awarded a $402,402 R21 project grant to the University of Louisville's Office of Research & Innovation. The goal of this 2-year grant, which began on September 19, 2023, is to develop and evaluate a novel tumor glycobiomarker-targeting agent called AVFC Lectibody as a potential immunotherapeutic and diagnostic agent against non-small cell lung cancer (NSCLC). The research aims to assess...